摘要
目的探究生长抑素联合乳酸菌治疗急性胰腺炎的临床疗效及对患者炎症因子、肠道黏膜屏障功能的影响。方法选取2021年8月至2022年10月萍乡矿业集团有限公司总医院收治的80例急性胰腺炎患者作为研究对象,依据随机数字表法分为对照组与观察组,每组40例。在常规治疗的基础上,对照组采用生长抑素治疗,观察组在对照组的基础上联合乳酸菌肠溶胶囊治疗。比较两组临床指标、治疗前后炎症因子水平和肠道黏膜屏障功能指标、不良反应发生情况及临床疗效。结果观察组腹胀腹痛缓解时间、血淀粉酶恢复时间、肠鸣音恢复时间、尿淀粉酶恢复时间、住院时间均短于对照组,差异有统计学意义(P<0.05)。治疗后,两组肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)水平均低于治疗前,白细胞介素-2(interleukin-2,IL-2)水平均高于治疗前,且观察组TNF-α、IL-6、IL-2水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组D-乳酸、血浆降钙素原水平及尿乳果糖/甘露醇比值均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论生长抑素联合乳酸菌可减轻急性胰腺炎患者炎症反应,恢复肠道黏膜屏障功能,促进患者恢复,且不增加不良反应发生风险,值得临床推广应用。
Objective To explore the clinical efficacy of somatostatin combined with lactic acid bacteria in the treatment of acute pancreatitis,and the effects on inflammatory factors and intestinal mucosal barrier function of patients.Methods 80 patients with acute pancreatitis admitted to the General Hospital of Pingxiang Mining Group Co.,Ltd.from August 2021 to October 2022 were selected as the study subjects,and they were divided into the control group and the observation group according to random number table method,with 40 cases in each group.On the basis of conventional treatment,the control group was treated with somatostatin,and the observation group was treated with aactic acid bacteria enteric-coated capsules on the basis of the control group.The clinical indexes,levels of inflammatory factors and intestinal mucosal barrier function indexes before and after treatment,occurrence of adverse reactions and clinical efficacy were compared betweeen the two groups.Results The relief time of abdominal distension and abdominal pain,the recovery time of blood amylase,the recovery time of bowel sounds,the recovery time of urine amylase and the hospital stay in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)of the two groups were lower than before treatment,while the levels of interleukin-2(IL-2)were higher than before treatment,and the levels of TNF-α,IL-6 and IL-2 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of D-lactic acid,plasma procalcitonin and urinary lactulose/mannitol ratio of the two groups were lower than before treatment,and the observation group was lower than control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups.The total effective rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Somatostatin combined with lactic acid bacteria can reduce the inflammatory reaction in patients with acute pancreatitis and restore the function of intestinal mucosal barrier,promote patient recovery,and does not increase the risk of adverse reactions,it is worthy of clinical promotion and application.
作者
李军
易珂韦
段帅
黄昕
LI Jun;YI Kewei;DUAN Shuai;HUANG Xin(Department of Emergency,General Hospital of Pingxiang Mining Group Co.,LTD.,Pingxiang,Jiangxi,337000,China)
出处
《当代医学》
2025年第4期21-25,共5页
Contemporary Medicine
关键词
急性胰腺炎
生长抑素
乳酸菌
不良反应
肠道黏膜屏障功能
Acute pancreatitis
Somatostatin
Lactic acid bacteria
Adverse reactions
Intestinal mucosal barrier function
